Increased left-ventricular mass after losartan treatment [4]

Lancet

Volumn 349, Issue 9067, 1997, Pages 1743-1744

  Cheung, Bernard ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

LOSARTAN; PEPTIDE HORMONE ANTAGONIST;

ADULT; BORDERLINE HYPERTENSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030970648     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)62955-8     Document Type: Article

References (5)

1. Caskey FJ, Thacker EJ, Johnston PA, Barnes JN. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 1997; 349: 620.
2. Lievre M, Gueret P, Gayet C, et al. Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. Hypertension 1995; 25: 92-97.
3. Cheung BMY, Lau CP. Fosinopril reduces left ventricular mass in patients with essential hypertension. Presented at the 5th International Symposium on ACE inhibition and other inhibitors of the renin-angiotensin system. Hong Kong, April, 1997.
4. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
5. Nozawa Y, Haruno A, Oda N, et al. Angiotenin II receptor subtypes in bovine and human ventricular myocardium. J Pharmacol Exp Ther 1994; 270: 566-71.